EUVIMEDEUVIMED entdecken
Crossref

Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot

Juan Chen, Jinjin Li, Xiaolu Sun, Huixia Lu, Kuai Liu, Zhenbo Li, Jianyue Guan, Huiling Song, Wei Wei, Yanhong Ge, Qiong Fan, Wei Bao und 2 weitere

Small · 2023

DOI: 10.1002/smll.202301043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2023. Verfasst von Juan Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchu…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Jiao Tong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heterogeneity and drug resistance of tumor cells are the leading causes of incurability and poor survival for patients with recurrent breast cancer. In order to accurately deliver the biological anticancer drugs to different subtypes of malignant tumor cells for omnidirectional targeted treatment of recurrent breast cancer, a distinct design is demonstrated by embedding liposome‐based nanocomplexes containing pro‐apoptotic peptide and survivin siRNA drugs (LPR) into Herceptin/hyaluronic acid cross‐linked nanohydrogels (Herceptin‐HA) to fabricate a HER2/CD44‐targeted hydrogel nanobot (named as ALPR). ALPR delivered cargoes to the cells overexpressing CD44 and HER2, followed by Herceptin‐HA biodegradation, subsequently, the exposed lipid component containing DOPE fused with the endosomal membrane and released peptide and siRNA into the cytoplasm. These experiments indicated that ALPR can specifically deliver Herceptin, peptide, and siRNA drugs to HER2‐positive SKBR‐3, triple‐negative MDA‐MB‐231, and HER2‐negative drug‐resistant MCF‐7 human breast cancer cells. ALPR completely inhibited the growth of heterogeneous breast tumors via multichannel synergistic effects: disrupting mitochondria, downregulating the survivin gene, and blocking HER2 receptors on the surface of HER2‐positive cells. The present design overcomes the chemical drug resistance and opens a feasible route for the combinative treatment of recurrent breast cancer, even other solid tumors, utilizing different kinds of biological drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleSurvivinHydrogelsTrastuzumabRNA, Small InterferingCell Line, TumorErb-b2 Receptor Tyrosine KinasesHyaluronan Receptors

Stichwörter der Autor:innen

CD44HER2drug resistanceheterogeneity of tumorrecurrent breast cancer

Substanzen

SurvivinHydrogelsTrastuzumabRNA, Small InterferingErb-b2 Receptor Tyrosine KinasesHyaluronan ReceptorsCD44 protein, human

Autor:innen und Institutionen

  • Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, China.
  • Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yi-Shan Road, Shanghai, 200233, China.
  • The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, 910 Hengshan Road, Shanghai, 200030, China.
  • Department of Obstetrics and Gynecology, Shanghai General Hospital affiliated with Shanghai Jiao Tong University, 100 Haining Road, Shanghai, 200080, China.

ORCID-Profile: Zixiu Du

Förderung

  • National Natural Science Foundation of China
  • Shanghai Jiao Tong University

Zitieren

APA

Chen, J., Li, J., Sun, X., Lu, H., Liu, K., Li, Z., Guan, J., Song, H., Wei, W., Ge, Y., Fan, Q., Bao, W., Ma, B., & Du, Z. (2023). Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot. Small. https://doi.org/10.1002/smll.202301043

Vancouver

Chen J, Li J, Sun X, Lu H, Liu K, Li Z, et al. Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot. Small. 2023. doi:10.1002/smll.202301043

BibTeX
@article{Chen2023,
  author = {Chen, Juan and Li, Jinjin and Sun, Xiaolu and Lu, Huixia and Liu, Kuai and Li, Zhenbo and Guan, Jianyue and Song, Huiling and Wei, Wei and Ge, Yanhong and Fan, Qiong and Bao, Wei and Ma, Buyong and Du, Zixiu},
  title = {Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot},
  journal = {Small},
  year = {2023},
  doi = {10.1002/smll.202301043}
}
Kostenlos starten →